The cyclin-dependent kinase-like 5 gene (CDKL5) is recognized as one of the genes responsible for epileptic encephalopathy. We identified CDKL5 mutations in five Japanese patients (one male and four female) with epileptic encephalopathy. Although all mutations were of de novo origin, they were located in the same positions as previously reported pathogenic mutations. These recurrent occurrences of de novo mutations in the same loci may indicate hot spots of nucleotide alteration.
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Epileptic encephalopathies are characterized by frequent and intractable seizures associated with severe neurological developmental delay. 1 To date, several genetic causes have been revealed, and epileptic encephalopathies are classified into subcategories according to the corresponding genetic alterations identified. 2 At present, an Online Catalog of Human Genes and Genetic Disorders (OMIM database; http://www.omim.org/) lists a total of 23 genes that are associated with the pathogenesis of epileptic encephalopathies. 3 The cyclin-dependent kinase-like 5 gene (CDKL5), which maps to chromosome Xp22 and contains 20 coding exons, is recognized as one of the genes responsible for a form of epileptic encephalopathy classified as early infantile epileptic encephalopathy 2 in OMIM (EIEE2; MIM#300672). To date, many nucleotide alterations associated with EIEE2 have been identified in CDKL5.
4-6 Previously, we reported the results of a cohort study for CDKL5 mutations involving 12 patients with CDKL5 alterations. 7 This study reports CDKL5 mutations identified by genetic diagnosis in five new patients.
This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tokyo Women's Medical University. Thirty-four newly recruited patients were enrolled into this study. All patients were diagnosed as having epileptic encephalopathy on the basis of clinical symptoms and electroencephalography results as described previously. 7 After obtaining written informed consent from the patients' families, blood samples were obtained from the patients and their parents, if necessary. DNA was extracted from these blood samples using a QIAamp DNA extraction kit (Qiagen, Hilden, Germany). Whole-genome copy number was analyzed using the SurePrint G3 Human CGH Microarray Kit 8 × 60 K (Agilent Technologies, Santa Clara, CA, USA) as described previously, 7 and no aberrations were found. All coding exons of CDKL5 were analyzed by the standard Sanger sequencing method as described previously. Although this alteration has not been reported previously, a different alteration at the same position affecting a splicing acceptor site, XM_005274584.1:c.404-1G4T, was reported as a pathogenic variant by Archer et al. 8 To confirm aberrant splicing, mRNA expression was analyzed by reverse-transcribed-PCR amplification and subsequent Sanger sequencing. In brief, total RNA extracted from the patient's lymphocytes was reverse-transcribed into complementary DNA, which was used as a template for PCR amplification by means of specific primers (sense 5′-CAAATGG AGTTCCACCTGAG-3′ and antisense 5′-AAGGCTGTCCATCGCTAAGC -3′). Normally, a 298 bp product is predicted to be amplified by this reverse-transcribed-PCR. After agarose gel electrophoresis, an abnormal short band was identified (Figure 2b ). The normal band and the abnormal short band were separated, and the DNA extracted from these bands was analyzed by Sanger sequencing. The sequencing results of the short band showed a skipping of exon 7 (Figure 2c ), which is predicted to cause a 60 bp deletion in the CDKL5 mRNA (XM_005274584.1:c.404-463del).
Patient 2 was a 19-month-old boy. At the age of 20 days, he experienced tonic convulsions that evolved into intractable epileptic spasms. A brain MRI performed at 19 months revealed no definitive abnormalities (Figures 1e,j) . No head control had been achieved to date. Patient 3 was a 4-month-old girl. She started to show tonic convulsions at the age of 20 days. A series of spasms were also observed. An electroencephalography showed multi-focal spikes. A brain MRI performed at 18 weeks demonstrated no definitive abnormality compared with an age-matched control (Figures 1f,k) . Patients 2 and 3 had the same mutation, XM_005274584.1:c.533G4A [p.(Arg178Gln)] (Figure 2a ). This missense mutation has been recurrently identified and was reported in our previous study 7 and also in a study by Zhao et al. 9 A different alteration in the same residue, c.533G4C Patient 4 was a 20-year-old woman. At 2 months of age, she started to show partial seizures associated with vocalization and tonic convulsions, which evolved into intractable epileptic spasms. A brain MRI performed at 20 years of age showed a mildly atrophic change in the brain (Figures 1b,g,l) . At present, the patient is unable to sit unassisted or articulate coherent and meaningful words. She was found to have XM_005274584.1:c.825 +1G4A, which affects a splicing donor site (Figure 2a) , as previously reported by Fehr et al.
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Patient 5 was a 26-month-old girl. She had experienced partial seizures associated with tonic convulsions at the age of 2 weeks. Her seizures were intractable, and she was diagnosed as suffering from West syndrome at the age of 15 months. A brain MRI at 19 months showed atrophic changes; however, these may have occurred as side effects of adrenocorticotropic hormone therapy (Figures 1c,h,m) . This patient was found to have XM_005274584.1: c.1675C4T [p.(Arg559*)] (Figure 2a ). This nonsense mutation has been recurrently identified and was reported in our previous study, 7 as well as by Sartori et al. 12 and Fehr et al.
As described above, we identified pathogenic mutations in CDKL5 in five unrelated patients with epileptic encephalopathy. All of the parents, except for the father of patient 4, were examined and did not show the mutations identified in the probands. Thus, the CDKL5 mutations identified in the five patients studied were of de novo origin. The detection ratio was 14.8%, which is similar to that reported in our previous study. 7 The gender ratio (four female:one male) of the patients was also similar to that in our previous study. 7 All patients showed intractable epilepsy and moderate to severe developmental delay. Thus, there was no phenotypic difference among the patients with different mutations. Brain MRIs showed no definitive structural abnormality in any of the patients, although brain atrophy was observed in patient 4 at 20 years of age (Figure 1) . Although the mechanism of this brain atrophy is unknown, this finding is commonly observed in patients with the CDKL5 disorder. 7, 13 In this study, all mutations were located at genomic positions where previously reported mutations have been identified. The genomic position of c.404-1G4A, which was first identified in this study, was the same as a previously reported mutation (c.404-1G4T), but the nucleotide alteration pattern of this mutation was different and novel. We confirmed in this study that this splicing acceptor site mutation did cause exon skipping.
In the literature, there are 31 locations in which mutations have been recurrently observed (Figure 2d) . 4, 14, 15 Among them, eight mutations (26%) were at splicing regions distributed throughout the CDKL5 gene. In contrast, the majority of the recurrent missense mutations are located in the catalytic domains. 6, 15 Furthermore, eight missense mutations (26%) were related to C to T (G to A) transitions observed in CG dinucleotide sequences. CG sites are prone to DNA methylation and nucleotide changes. 16 Therefore, these locations are considered as mutation hot spots and would be important for CDKL5 function. 
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